Bell C, Tandon P, Lentz E, et al. - Researchers aimed to compare pregnancies of women with inflammatory bowel disease exposed to vedolizumab vs those on other treatments with respect to maternal and fetal adverse outcomes. Via performing a systematic literature search through December 2020, they identified four studies meeting criteria for the primary analysis. Findings highlight possible concern with the general safety of VDZ in pregnancy, as there was an increase in overall total unfavorable outcomes. Pregnant female patients on vedolizumab had greater prevalence of premature births and early loss of pregnancy.